<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03633513</url>
  </required_header>
  <id_info>
    <org_study_id>LBT-PD-003</org_study_id>
    <nct_id>NCT03633513</nct_id>
  </id_info>
  <brief_title>Parkinson's Disease Inflammatory Biomarker Profiling</brief_title>
  <official_title>Inflammatory Parkinson's Disease (PD) Clinical Biomarker Profiling in T Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Longevity Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Corporal Michael J. Crescenz VA Medical Center - Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Longevity Biotech</source>
  <oversight_info>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares a comprehensive panel of immunological biomarkers between Parkinson's
      disease patients and healthy, environmentally matched participants. This unique study design
      provides the ability to control for differences in environment between study subjects. The
      goal of this study is to 1) identify a specific set of immunological markers that correlate
      with a clinical diagnosis of Parkinson's disease and 2) stratify patients by disease severity
      using these same biomarkers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Unified Parkinson Disease Rating Scale</measure>
    <time_frame>1 hour</time_frame>
    <description>Clinical scoring system to evaluate severity of Parkinson's disease in patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interleukin-17</measure>
    <time_frame>48 hours</time_frame>
    <description>Proinflammatory cytokine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FoxP3</measure>
    <time_frame>48 hours</time_frame>
    <description>Regulatory Tcell marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GM-CSF</measure>
    <time_frame>48 hours</time_frame>
    <description>Cytokine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LRRK2</measure>
    <time_frame>48 hours</time_frame>
    <description>Leucine rich region kinase 2 protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VPAC2</measure>
    <time_frame>48 hours</time_frame>
    <description>Regulates TH1/TH2 balance of inflammatory system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interferon gamma</measure>
    <time_frame>48 hours</time_frame>
    <description>Inflammatory cytokine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor necrosis factor alpha</measure>
    <time_frame>48 hours</time_frame>
    <description>Inflammatory cytokine</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immune cell functional analysis</measure>
    <time_frame>1 week</time_frame>
    <description>Performance evaluation of protective immune cells (Tregs) compared to responder immune cells (Tresp)</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Clinical diagnosed Parkinson's disease patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caregivers</arm_group_label>
    <description>Environmentally matched healthy control subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>LBT-3627</intervention_name>
    <description>Immunomodulatory agent</description>
    <arm_group_label>Caregivers</arm_group_label>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Immunological profiling</intervention_name>
    <description>Comprehensive profiling of inflammatory and anti-inflammatory markers (incl. cellular, molecular) including cellular functional assays</description>
    <arm_group_label>Caregivers</arm_group_label>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with Parkinson's disease and their caregivers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

        All Participants

          -  Subjects must be willing and able to participate in study

          -  Subjects must be willing and able to provide written consent to participate.

          -  Subjects must be willing and able to comply with scheduled clinic visits and study
             procedures (UPDRS exam, blood draw and complete a questionnaire)

          -  Subjects are not currently taking an immunomodulatory (e.g. anti- tumor necrosis
             factor (TNF), immunosuppressants/stimulants) agent in the past 90 days

          -  No active or recent (&lt; 3 weeks) infection requiring clinical intervention and/or
             pharmaceutical treatment or febrile neutropenia within the last week.

          -  18-89 years old

        Parkinson's Disease Patients

          -  Clinical diagnosis of PD by a movement disorders specialist consistent with standard
             criteria

          -  Able to attend a clinical visit in the 'off' state

          -  Hoehn and Yahr stage I-IV

        Caregiver Controls

        • Individuals without PD who share environmental exposures (i.e. spouses, children,
        caregivers or other individuals who frequently spend significant time (&gt;6 hours) in
        proximity to the PD subject) OR age and sex matched healthy individuals from general
        population

        Exclusion Criteria

        All Participants

          -  Unstable cardiopulmonary or cerebrovascular disease

          -  Renal disease or failure w/ serum creatinine greater than 2.5

          -  Severe or unstable depression or other axis I psychopathology

          -  Epilepsy

          -  Prior brain surgery related to PD (DBS, cell implantation, gene therapy, etc.)

          -  Severe head injury with evidence of brain injury

          -  Essential Thrombocythemia (ET) (&gt;450,000 platelets/mL)

          -  Patients currently being treated with any of the following, within the past 5 days:

          -  Immunomodulatory agents (e.g. Remicade®, Humira®, Enbrel®) (within the past 90 days)

          -  Corticosteroids

          -  Probenecid®

          -  Coenzyme Q10®

          -  Anticoagulants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Shandler, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Longevity Biotech, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scott Shandler, PhD</last_name>
    <phone>215-689-1042</phone>
    <email>scott@longevitybiotech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Corporal Michael J. Crescenz VA Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Longevity Biotech, Inc</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Shandler, Ph.D.</last_name>
      <phone>215-689-1042</phone>
      <email>clinical@longevitybiotech.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://foxtrialfinder.michaeljfox.org/trial/5308/</url>
    <description>Michael J. Fox Trial Finder</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>July 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>May 20, 2019</last_update_submitted>
  <last_update_submitted_qc>May 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immune System</keyword>
  <keyword>Immunology</keyword>
  <keyword>Neuroinflammation</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Neuroprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

